Derms on Drugs

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.We cover:Can moisturizing infants prevent atopic dermatitis?New sunscreen ingredients headed for the US marketInsights from lichenoid eruptions linked to immune checkpoint inhibitorsWhat to do if oral JAKs fail in alopecia areataDoes CeraVe outperform other moisturizers?The real risk of cardiovascular and thromboembolic events with JAK inhibitorsWhy IL-13 inhibitors differ in likelihood of causing arthralgiasAdvances in autologous skin cell transplantation for vitiligoThe safety of patients self-injecting triamcinolone for acneNew findings on hypersensitivity reactions after sentinel lymph node biopsyCan patch testing help with burning mouth syndrome?A drug that reduces cardiovascular mortality in hidradenitis suppurativaNovel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosisJoin us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.Listen now and stay ahead in dermatology!

Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.In this episode, we tackle:-What network meta-analyses actually measure and how they're conducted-Why two NMAs can reach opposite conclusions about drug effectiveness-Red flags to watch for when evaluating NMA quality and reliability-Practical guidance for incorporating NMA findings into clinical practicePerfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.Listen now to become a smarter consumer of dermatology research! And be sure to discover more at Scholars In Medicine!

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers. We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above.  Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!So join us for a deep dive into CSU, and yes, there will be trivia at the end!Visit the ⁠Scholars In Medicine⁠ website for more.

Get ahead of the curve with Derms on Drugs as we break down the most exciting new dermatology research! This week features game-changing studies including an oral probiotic with stunning results for atopic dermatitis, JAK inhibitors for bullous pemphigoid, and IL-23 inhibitors tackling guttate psoriasis.Plus, we dive deep into:Dermoscopy advances for managing longitudinal melanonychiaIf failing an IL-13 inhibitor affects the chances of doing well on another IL-13 inhibitorNew data on IL-13 inhibitor induced conjunctivitisRed light PDT efficacy for superficial basal cell carcinomaEarly systemic PDE4 inhibition strategies in psoriasisFollicular event insights from tapinarof studiesPDE4 inhibition potential for vitiligo treatmentPerfect for dermatology providers who want cutting-edge clinical pearls they can apply immediately. Tune in for evidence-based insights, practical takeaways, and the signature Derms on Drugs commentary that keeps you engaged while staying current.See more at ScholarsInMedicine.com

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling all kinds of medical diseases - whether we're talking about patients who can't access (or don't respond adequately) to our highly effective FDA approved drugs for psoriasis, atopic dermatitis, alopecia areata, hidradenitis or about patients with diseases that don't have an extremely effective FDA approved drug - things like lichen planus, granuloma annulare, dermatitis herpetiformis and many, many more.  This week, we talk through dapsone, roflumilast, and acitretin.In this episode, you’ll learn:Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.Tune in for clinical pearls and expert insights you can put to work in your practice!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.In this episode, you’ll learn:--When and why to reach for these time-tested therapies in real-world practice--How to monitor labs and counsel patients for safety and success--Tips for discussing off-label treatments and navigating complex casesPerfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.Tune in for clinical pearls and expert insights you can put to work in your practice!Article titles:1.  Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial2.  Lower Oncogenic Risk with Dermatologic Use of Mycophenolate Mofetil Compared to Transplant Prophylaxis: A Retrospective Study3.  Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Today on Derms on Drugs we’ve got the fabulous Dr. Heather Woolery-Lloyd with us, and yes—we’re talking sunscreens. Don’t roll your eyes, because we’re going way past “SPF 30 or 50?” into the good stuff: how these lotions and potions actually work, which myths need to finally get buried, and why tinted sunscreens aren’t just makeup but legit medicine for skin of color.We’ll also dish on the brand-new Aussie rules for UV protection and spill which brands actually look good on darker skin without turning you into a ghost.And because no episode is complete without it, we’ll detour into lifestyle hacks, chat a little nutrition, and finish with our usual trivia shenanigans.So, grab your SPF (tinted or not, we don’t judge), and let’s dive in"

Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!What’s on Tap in Our 6 Pack Episode?Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:New Therapy for Recessive Dystrophic Epidermolysis Bullosa: We’re walking through the latest clinical trial that could be a real gamechanger.Homemade vs. Commercial Sunscreens: Should your patients blend SPF cocktails in the kitchen, or is that a recipe for disaster?Immunosuppressives and Patch Testing: Just how “immunosuppressed” can your patients be and still get valid patch testing results? We’ve got the hottest updates from the experts—no immuno-anxiety required.HPV Vaccine vs. Actinic Keratoses: A blockbuster therapy for warty issues? This clinical trial investigates the HPV vax as a new weapon in the fight against actinic keratoses.Hailey-Hailey Disease Treatment Algorithms: Confused by this rare disease? We’re breaking down shiny new algorithms so you can manage it like a pro.JAK Inhibitor Discontinuation and Heart Risks: Why do patients sometimes trade clear skin for cardiac drama after stopping a JAK inhibitor? The science just got spicier, and we’ve got the scoop.So scrub in, sit back, and let us put the “fun” in fundamentals as we break down the latest, greatest (and occasionally weirdest) in the world of clinical dermatology. Let’s pop open that six-pack and get started.And for links to all of the articles we discussed in this episode, visit ScholarsInMedicine.com

Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:Review three of the hottest papers on bullous pemphigoid, dissecting the latest evidence with our signature blend of rigor and irreverence.Break down the recent FDA approval of dupilumab for bullous pemphigoid—a new kid on the blister block!Unpack the pivotal dupilumab study results, then pit them against real-world evidence. Does the hype hold up outside the ivory tower?Debate how we’ll actually integrate dupilumab into our clinical arsenal. Is this a game-changer or just another tool in the kit?Explore the real impact on patient care: Will this approval mean fewer steroids, better outcomes, or simply more options for those tough-to-treat cases?Refresher course in bullous pemphigoid - diagnosis and practical treatment pearlsSo, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.For Links to articles please go to ScholarsinMedicine.com1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.We break down the newest literature and answer:Does immunotherapy really help with high-risk squamous cell carcinoma?Are pemphigus patients getting more rituximab than they need?Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?Is the Mind.Px test actually helpful for picking a psoriasis biologic?What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?Which treatment factors predict scabies cure?Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!Hit play and stay on the cutting edge of medical dermatology!1.  Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma2.  Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial3.  Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium4.  Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis5.  Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes6.  Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab7.  Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.We’re joined by CSU expert Dr. Jason Hawkes to discuss:-How Dupixent is changing the game for CSU and why dermatologists are leading the charge-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients-How we explain to CSU patients that they don’t need allergy testing!-Clinical pearls for work-up, navigating treatment guidelines, safety, and accessPerfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.Hit play and stay ahead on the cutting edge of CSU care!1.  Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound2.  Remibrutinib in Chronic Spontaneous Urticaria3.  Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.This week, we break down:Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitisThe future of autoimmune disease treatment: genetically modified T cellsWhat policies people actually support (and will pay for) to reduce skin cancer ratesJAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch forThe latest on rising contact allergens: which ones are on the move and whyPacked with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.Don’t miss out—hit play for your weekly dose of dermatology insights!For links to all articles visit ScholarsinMedicine.com1.  Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study2.  Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid3.  Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry4.  Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study5.  Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents6.  Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries7. North American Contact Dermatitis Group Patch Test Results: 2021–2022

Ever feel overwhelmed by the flood of alopecia treatments and supplements?Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.In this episode, we tackle:Which labs to order for telogen effluviumWhich hair loss supplements are actually worth recommendingThe truth about red light helmetsHow and when to use prescription therapies for hair lossCan shampoo really help with alopecia?Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.Listen now for all the answers—and maybe a few laughs!

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them.  Derms on Drugs to the rescue.  In part one of our deep dive into hair loss we cover three big topics:  1) What supplements for hair loss actually work?  You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diagnosing and managing folliculitis decalvans?  Join us for another episode with our trademark mix of evidence and banter!  #DermatologyPodcast #HairLoss #DermsOnDrugs #AlopeciaProduced by ScholarsinMedicine.comScholarsinMedicine.com⁠1.  Management of folliculitis decalvans: The EADV task force on hair diseases position statement2.  Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience3.  Impact of Laboratory Work Up and Supplementation on Alopecia Patients: A Single-Center Retrospective Chart Review4.  Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss A Systematic Review

 Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.Derms on Drugs is a production of Scholarsinmedicine.com1.  Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US2.  Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis3.  AI Description and Answers About How Drug Pricing WorksScholarsinmedicine.com

Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection. World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively banter that’ll make you a smarter clinician. Don’t miss this chance to stay ahead in the AI revolution!Derms on Drugs is produced by ⁠Scholars In MedicineFor Resources links visit: ⁠Scholars In Medicine⁠1.  Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?2.  3D Total-Body Photography in Patients at High Risk for Melanoma3.  Promises and Pitfalls of 3D Total-Body Photography for Melanoma Early Detection4.  Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance5.  Standard Dermatoscope Images vs an Autonomous Total Body Photography and Dermoscopic Imaging Device

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!In This Episode:Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?Dermatomyositis: Consequences of misdiagnosis and delayed diagnosisVitiligo: Could hydroxychloroquine be a game-changer over NBUVB?Skin Inflammation: A key driver of food allergyPemphigoid: Insights into immunotherapy-induced casesPremenstrual Rashes: Managing flares in atopic1.  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.2.  Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis3.  Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial4.  Skin damage signals mediate allergic sensitization to spatially unlinked antigen5.  Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid6.  The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review7.  Nickel contact allergy and menstrual cycle8.  Autoimmune progesterone dermatitis: Update and insightsDerms on Drugs is produced by ⁠⁠Scholars in Medicine.com

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation1.  Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study ScholarsInMedicine.com2.  The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer3.  Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study